GLP-1s Got That Rizz: The Future of MASH and Metabolic Syndrome Care

Statement of Need

With recent approvals of semaglutide and resmetirom, the treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) has entered a new era. In this final webisode of a 4-part CME Outfitters series, expert faculty look ahead to the next wave of therapeutic innovation. This session reviews emerging strategies that build on recently approved agents, including combination approaches aimed at improving steatohepatitis, fibrosis, and cardiometabolic risk. Particular attention is given to novel incretin-based therapies, including GLP-1 receptor/glucagon receptor dual agonists, which may offer enhanced metabolic and hepatic benefits. Additionally, faculty will explore the clinical promise of fibroblast growth factor 21 (FGF-21) analogues—agents with pleiotropic activity that may address liver injury while also targeting extrahepatic manifestations such as obesity, insulin resistance, and dyslipidemia.

This fourth Snack in the series features experts Naim Alkhouri, MD, and Monica Tincopa, MD, MSc, who together provide practical insights and forward-looking perspectives on where MASH management is headed and what to anticipate in clinical practice.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Evaluate the potential role of GLP-1 RAs in the future treatment of MASH and other components of the metabolic syndrome

Financial Support

Supported by an educational grant from Novo Nordisk Inc.

Target Audience

Physicians, nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists treating patients with MASH

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.50 contact hours ( 0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-25-098-H01-P).

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 0.50 Contact Hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Physician Associates (AAPA): 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 11/13/2026. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Tincopa reports the following financial relationships:

Consultant: AbbVie Inc. and Optum, Inc.

Dr. Alkhouri reports the following financial relationships:

Advisory Board: 89bio, Inc.; AbbVie Inc.; Akero Therapeutics, Inc.; Boehringer Ingelheim; Echosens; Fibronostics; Gilead Sciences, Inc.; Histoindex; Intercept Pharmaceuticals, Inc.; Ipsen Pharma; Madrigal Pharmaceuticals, Inc.; NorthSea Therapeutics; Novo Nordisk; Perspectum; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.

Research Support: 89bio, Inc., Inc.; Akero Therapeutics, Inc.; Arbutus Biopharma; AstraZeneca; BioAge; Boehringer Ingelheim; Bristol Myers Squibb Company; Corcept Therapeutics; Galectin Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; Hepagene Therapeutics, Inc.; Intercept Pharmaceuticals, Inc.; Inventiva; Ionis Pharmaceuticals, Inc.; Ipsen Pharma; Lilly; Madrigal Pharmaceuticals, Inc.; Merck & Co., Inc.; NGM Biopharmaceuticals; NorthSea Therapeutics; Novo Nordisk; Perspectum; Pfizer Inc.; PharmaIN Corp.; Poxel; Regeneron Pharmaceuticals Inc.; Viking Therapeutics; and Zydus Pharmaceuticals, Inc.

Speakers Bureau: AbbVie Inc.; AstraZeneca; Echosens; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Ipsen Pharma; Madrigal Pharmaceuticals, Inc.; and Novo Nordisk

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Susan Perry (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-286-111325-68